Navigating the bumpy road ahead: stakeholder perspectives on EU HTAR
As the European Union's Health Technology Assessment Regulation (EU HTAR) prepares to take effect on January 12, 2025, stakeholders across the healthcare ecosystem are faced with a pivotal opportunity to reshape the evaluation and adoption of new medicines and health technologies. The regulation promises a harmonized framework for assessing clinical evidence, reducing redundancies across Member States, and fostering collaboration in health technology assessment. However, the path to achieving these ambitious goals is neither straightforward nor without challenges.
During ISPOR Europe 2024, Herbert Altmann (Cencora, Germany) led an informative session exploring the topic, “Ready for 2025? How Lessons Learned From National System Reforms Can Guide Our Response to the New EU HTA Regulations.” The discussion focused on recent HTA reforms in Germany, Spain, France and Poland, examining stakeholder readiness for the EU HTAR and how shared experiences can enhance preparedness.
Sections:
- Streamlining evidence generation for equitable access to treatments across the EU
- Germany’s perspective: balancing national processes and harmonization
- France’s perspective: evolution not revolution
- Spain’s perspective: commitment to change
- Poland's perspective: embracing opportunities and overcoming challenges
- Pharmaceutical industry perspective: leveraging EU HTAR for streamlined access and collaboration
- Clinician and patient perspective: Building engagement for long-term success
Click below to read the full article, and to understand perspectives from different EU Member States on the eve of this important implementation.
Sponsorship for this Deep Dive was provided by Cencora.